Aquinnah Pharmaceuticals, Inc.

Aquinnah Pharmaceuticals develops small molecule therapeutic drugs to treat neurodegenerative diseases such as Alzheimer's disease and ALS by targeting pathologic biomolecular condensates formed by RNA-binding proteins. The company's approach is based on research into stress granules and their role in disease progression, with preclinical studies demonstrating significant reduction in brain tau pathology associated with Alzheimer's disease.